|Author:||G. Giraldo,M. Salvatore,M. Piazza,D. Zarrilli,E. Beth-Giraldo,A. Dalhoff,H. Schönfeld|
|Publisher:||S. Karger; 1 edition (May 14, 1991)|
|Other formats:||azw lrf doc mbr|
Based on an international advanced course on 'AIDS and Associated Tumors', Naples, Italy, March 15, 1990.
Based on an international advanced course on 'AIDS and Associated Tumors', Naples, Italy, March 15, 1990. Published: 1 January 1991. in Antibiotics and chemotherapy. Antibiotics and chemotherapy, Volume 43. PubMed.
Tumour-associated macrophages, TAMs, play a pivotal role in tumour growth and metastasis by promoting tumour angiogenesis. Treatment with clodronate encapsulated in liposomes (clodrolip) efficiently depleted these phagocytic cells in the murine F9 teratocarcinoma and human A673 rhabdomyosarcoma mouse tumour models resulting in significant inhibition of tumour growth ranging from 75 to 92%, depending on therapy and schedule. Tumour inhibition was accompanied by a drastic reduction in blood vessel density in the tumour tissue
Biomedical and social developments in AIDS and associated tumors. Based on an international advanced course on 'AIDS and Associated Tumors', Naples, Italy, March 15, 1990.
Biomedical and social developments in AIDS and associated tumors. pmid: 1679320 Antibiot Chemother (1971) 影响因子: . 发表日期: 19910101. AIDS (Disease), Acquired Immunodeficiency Syndrome, Complications, Congresses, Etiology, Neoplasms.
Giraldo, G. (Gaetano). C) 2017-2018 All rights are reserved by their owners. On this site it is impossible to download the book, read the book online or get the contents of a book. The administration of the site is not responsible for the content of the site.
A tumor is an abnormal mass of tissue that may be benign, premalignant, or cancerous. Some benign tumors can become premalignant and then malignant. For this reason, it is best to monitor any growth. Find out more about the types of tumor and the outlook for people with each type. Most benign tumors are not harmful, and they are unlikely to affect other parts of the body. However, they can cause pain or other problems if they press against nerves or blood vessels or if they trigger the overproduction of hormones, as in the endocrine system. Examples of benign tumors include: Adenomas.
Background Treatment with tumor necrosis factor (TNF) antagonists has been recognized as a risk factor for active tuberculosis (TB), particularly for reactivation of latent infection. Advancing knowledge of CD pathogenesis and recent advances in biotechnology have led to the development of biological agents that selectively target individual inflammatory pathways.
The most frequently diagnosed HIV-associated cancer is Kaposi’s sarcoma .
The most frequently diagnosed HIV-associated cancer is Kaposi’s sarcoma (KS) followed by AIDS-related non-Hodgkin lymphoma (ARL) . AIDS-related KS and ARL are distinct from their counterparts seen in HIV-1 seronegative patients. Several other types of tumors occur with increased frequency in AIDS patients including leiomyosarcoma in children, squamous cell carcinoma of the conjunctiva and multi-centric Castleman’s disease. It is likely that as the epidemic expands and AIDS becomes more of a chronic condition the spectrum of HIV-associated cancer will also evolve.
During the extended clinically latent period associated with Human . A survey of people living with AIDS in New York city found that female gender.
During the extended clinically latent period associated with Human Immunodeficiency Virus (HIV) infection the virus itself is far from latent. This phase of infection generally comes to an end with the development of symptomatic illness. Understanding the factors affecting disease progression can aid treatment commencement and therapeutic monitoring decisions. A survey of people living with AIDS in New York city found that female gender, older age, non-Caucasian race and transmission via injecting drug use or heterosexual inter-course were all associated with significantly higher mor-tality.
This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease oriented manner. Sections on all recognized neoplasms and their variants further include new ICD-O codes, epidemiology, clinical features, macroscopy, prognosis and predictive factors.